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distribution, discount rate and non performing transplant.
RESULTS: In the combined analysis, considering the expected
genotypic distribution for the Portuguese population, treatment
with PEGIFN+RIB was estimated to increase discounted life
expectancy by 1.61 years (23.30 vs 2169) and quality-adjusted
life expectancy by 1.17 QALYs compared to no treatment. Direct
costs were projected to be €29,410 with PEGIFN+RIB and
€33,788 with no treatment. These results corresponded to ICERs
of -€2.19 and -€3742 per life year gained and per QALY gained,
respectively. CONCLUSIONS: The use of of PEGIFN+RIB
(PEGASYS/COPEGUS) vs no treatment in patients with HIV/
HCV co-infection is a cost-saving (dominant) alternative in the
Portuguese setting for all genotypes.
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OBJECTIVES: To estimate the cost-effectiveness of caspofungin
versus amphotericin B, voriconazole, and anidulafungin in the
treatment of invasive candidiasis in a subgroup of patients who
are infected by ﬂuconazole-resistant Candida species and in
patients who cannot be treated with ﬂuconazole due to other
reasons. METHODS: For this analysis a lifetime Markov model
was used with following health states: success, failure, and death
over two treatment lines. A randomized clinical trial comparing
caspofungin and amphotericin B was used to estimate daily tran-
sition probabilities. The corresponding probabilities for vori-
conazole and anidulafungin were estimated based on indirect
comparisons using amphotericin B as the common comparator.
The analysis was conducted from a societal perspective. Direct
costs inside the health care system were included. Outcomes were
reported as cost per life-year gained. To determine the robustness
of the model and the impact of uncertainty, uni- and multivariate
sensitivity analyses were carried out. RESULTS: In the base case
analysis the 95% conﬁdence intervals of the incremental life
years were estimated at 0.23(-0.29, 0.85), 0.21(-0.31, 0.88),
and 0.11(-0.37, 0.71) compared to amphotericin B, voricona-
zole, and anidulafungin respectively. Corresponding intervals for
incremental costs were €1825(-€3954, €5581), €40(-€5243,
€3354), and -€415(-€4938, €2570). Cost per life year gained
was €7942 and €189 compared to amphotericin B and voricona-
zole. Caspofungin was dominant compared to anidulafungin.
Probabilistic sensitivity analyses showed that at a willingness to
pay threshold of €20,000/QALY, caspofungin has a 62%, 72%,
and 68% probability to be cost-effective relative to respectively
amphotericin B, voriconazole and anidulafungin. Univariate sen-
sitivity analyses showed that results were sensitive to changes in
efﬁcacy parameters and infection-related mortality. CONCLU-
SIONS: The present model suggests that caspofungin is cost-
effective in the treatment of invasive candidiasis in this speciﬁc
subgroup of patients. Potential limitation of the model is that
efﬁcacy and failure estimates are partly based on indirect
comparisons.
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OBJECTIVES: This study evaluated the cost-effectiveness of
peginterferon alfa-2b (1.5 mcg/kg/wk) plus 800–1400 mg/day
ribavirin (PEG2b 1.5/R) in patients with refractory chronic
hepatitis C (HCV) whose previous combination therapy with
pegylated or standard interferon alfa and ribavirin failed.
METHODS: A Markov model was developed based on an
open-label trial (EPIC) in which patients received PEG2b 1.5/R
or no further drug therapy. Patients with genotypes 1/4 (G1/4)
HCV with undetectable HCV RNA at week 12 were treated for
48 weeks; patients with detectable HCV RNA were discontin-
ued at 18 weeks. G2/3 HCV patients were treated for 24
weeks. Data on the natural history of disease, drug and medical
resource costs (2007 euros), and utility values were estimated
from published literature. Using a Spanish perspective, the
model estimated the incremental cost-effectiveness ratio (ICER)
for PEG2b 1.5/R vs. no further treatment based on cost per
quality-adjusted life year (QALY) gained over a patient’s life-
time. A second-order probabilistic Monte Carlo sensitivity
analysis was conducted to assess the effects of parameter uncer-
tainty (efﬁcacy) on the study ﬁndings. RESULTS: In G1 and G4
patients, PEG2b 1.5/R led to higher costs (€19,300 vs. €10,100)
and increased QALYs (10.62 vs. 10.15) compared with no drug
therapy (ICER: €19,600 per QALY gained). In G2/3 patients,
treatment costs were twice as high for the PEG2b 1.5/R
regimen compared with no therapy (€22,200 vs. €10,100); the
incremental gain in QALYs was greater than it was for the G1
and G4 groups (11.99 vs. 10.15) (ICER: €6,600 per QALY
gained). The probabilistic sensitivity analysis suggests a 99%
probability that the ICER for PEG2b 1.5/R among refractory
patients is at or below a €30,000 per QALY gained threshold
for both genotype groups. CONCLUSIONS: PEG2b 1.5/R is in
the range of the widely accepted cost-effectiveness threshold for
medical interventions in Spain.
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OBJECTIVES: To systematically review the evidence for long-
term effectiveness and cost-effectiveness of screening for hepatitis
C virus (HCV) infection. METHODS: We performed a system-
atic literature search (March 2007) on the long-term health and
economic effects of HCV screening. We included health technol-
ogy assessment (HTA) reports, systematic reviews, long-term
clinical trials, full health economic studies and decision-analytic
modelling studies assessing the impact of HCV screening with a
sufﬁciently long time horizon and a patient-relevant long-term
outcome such as life-years gained (LYG) or quality-adjusted life
years (QALY) gained. Economic results were converted to 2005
Euros. RESULTS: Ten studies were included. Target population,
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HCV prevalence, study perspective, discount rate, screening and
antiviral treatment mode varied. The incremental effectiveness
of HCV screening and early treatment compared to no screen-
ing and standard care varied from 0.0004 LYG to 0.066 LYG
(0.0001–0.072 QALY). Incremental cost-effectiveness ratios
(ICER) of HCV screening versus no screening ranged from
18,300 to €1,151,000/QALY. HCV screening seems to be
cost-effective in populations with high HCV prevalence
(€18,300–46,700/QALY), but is associated with higher ICER in
populations with an average HCV prevalence. CONCLUSIONS:
Based on current evidence, HCV screening and early treatment
has the potential to improve life-expectancy and quality-adjusted
life-expectancy, but should focus on populations with elevated
HCV prevalence in order to be cost-effective. Further research on
the long-term health-economic impact of HCV screening when
combined with appropriate monitoring strategies in different
European health care systems is needed.
PIN30
COST-EFFECTIVENESS ANALYSIS OF DROTRECOGIN ALFA
(ACTIVATED; DAA) AS ATREATMENT FOR SEVERE SEPSIS
WITH MULTIPLE ORGAN FAILURE (MOF) IN POLAND
Kuzma J1, Kawalec P1, Bochenski P2
1Centrum HTA, Krakow, Poland, 2Ely Lilly,Warsaw, Poland
OBJECTIVES: To determine cost-effectiveness and cost-utility of
DAA added to standard care compared to standard care in the
treatment of severe sepsis with MOF from public payer’s per-
spective in Poland. METHODS: Results of a systematic review
of published clinical trials conducted according to Polish HTA
Guidelines were used to assess effectiveness and safety of DAA.
Data on reduction of 28-day all-cause mortality and probability
of adverse events for patients treated with DAA or with standard
treatment reported in this study, baseline mortality of sepsis
patients in Poland, probability of death during four years follow-
ing intensive care and life tables for general population were
incorporated into the decision tree model. A 24-year analytic
horizon was established as life expectancy in general population
of the same age and gender characteristics as sepsis patients.
Epidemiology data were obtained from Polish Sepsis Registry.
Cost-utility analysis was performed using utilities for sepsis
patients and general population—derived from published litera-
ture. Costs of treatment valid from public payer’s perspective
were taken into account. Costs of DAA, intensive care unit
hospitalization, parenteral nutrition, physician consultations,
bleeding and thrombotic events were included. All calculations
were performed for 2007 (1EUR = 3.8PLN). Only effects were
discounted (at 5% rate), as no costs occur beyond 1 year. Sensi-
tivity analysis was conducted assuming range of cost for DAA,
length of ICU stay, length of parenteral nutrition and discount
rate for effects. RESULTS: Adding DAA to standard therapy of
patients with severe sepsis and MOF signiﬁcantly reduces 28-day
mortality. Cost-effectiveness ratios are below the established
thresholds (ICER = 42,517PLN, ICUR = 58,615PLN). Sensitiv-
ity analysis showed that these results are robust. CONCLU-
SIONS: DAA added to conventional treatment of severe sepsis
with two or more organ dysfunctions is cost-effective from polish
public payer’s perspective.
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OBJECTIVES: According to international HIV treatment
guidelines, the goal of highly active antiretroviral treatment
(HAART) is to reduce viral load to undetectable levels (<50
copies/mL). Two therapies have recently been introduced in the
US with similar indications for treatment-experienced patients:
etravirine (TMC125, ETR) and raltegravir (RAL). This analysis
compares the relative cost of each therapy to reach the treat-
ment goal. METHODS: The proportion of patients reaching
undetectable viral load (<50 copies/mL) was reported in the
phase III trials that compared each drug to placebo in the pres-
ence of optimized background regimen (OBR): DUET 1&2
(ETR) and BENCHMRK 1&2 (RAL). No head-to-head trials
comparing ETR and RAL are available, so an indirect compari-
son at week 24 was made. The trials studied similar treatment-
experienced HIV-1 infected patients, but the composition of the
OBR differed. All patients received background darunavir/
ritonavir (DRV/r) in the DUET trials, while less than half
received background DRV/r in the BENCHMRK trials. Sub-
group data from the BENCHMRK trials provided a ‘prior’ esti-
mate of the treatment effect modiﬁcation due to DRV/r use. A
Bayesian analysis was used to adjust for differences in back-
ground DRV/r use between trials. The current analysis esti-
mated the treatment effect assuming that all patients received
background DRV/r. After adjusting for differences in the trials,
efﬁcacy and wholesale acquisition drug costs were analyzed.
RESULTS: The two new agents demonstrate a similar treat-
ment effect when adjusting for differences in OBR. Mean odds
ratios (95% CI) vs. placebo are: ETR 2.08 (1.64–2.6) and RAL
1.92 (0.98–3.42). The annual drug costs are $7957 for ETR
and $9855 for RAL. CONCLUSIONS: Based on the results
showing similar efﬁcacy rates in reaching the treatment goal of
<50 copies/mL, a cost-minimization approach can be taken
when evaluating the addition of ETR or RAL to a HAART
regimen for treatment-experienced patients.
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OBJECTIVES: To test the hypothesis of a reduction in total
medical costs we conducted a cost-study analysis in the setting of
a randomized open-label study comparing an intermittent to a
continuous antiretroviral regimen. METHODS: A total of 403
HIV-1-infected adults who were well tolerating HAART were
randomly assigned to switch to a ﬁxed 8-week off 8-week on
intermittent regimen (IT), or to maintain their current treatment
strategy (CT). The primary end point was the proportion of
patients who reached a CD4 cell count below 300 cells/ml
through 96 weeks. Costs were estimated from the viewpoint of
the payer over the 96-week study period. Resources were costed
from the national reimbursement schedules for hospital in and
out patient admissions and visits and the national selling price for
medications. RESULTS: Complete cost data were available for
391 patients (194 patient in the CT and 197 in the IT arms). The
mean cost per patient over the 96 weeks follow-up (excluding
protocol-driven costs) was €16,162 in the CT arm versus €9738
in the IT arm, a €6424 difference almost entirely due to the
difference in HAART cost. Protocol-driven costs represented
€280 in the CT versus €290 in the IT arm. The use of IT achieved
a 40% reduction in the total cost of HAART. CONCLUSIONS:
Reducing by 40% the cost of HAART medications in a treatment
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